Syndax Pharmaceuticals, Inc. (SNDX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.50B USD. 52-week range 12.99 to 25.59 USD. Data as of 2026-10-09.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a ...